[go: up one dir, main page]

UA122847C2 - Лікувальний комплекс для лікування діабету другого типу та діабетичної дисліпідемії - Google Patents

Лікувальний комплекс для лікування діабету другого типу та діабетичної дисліпідемії

Info

Publication number
UA122847C2
UA122847C2 UAA201906759A UAA201906759A UA122847C2 UA 122847 C2 UA122847 C2 UA 122847C2 UA A201906759 A UAA201906759 A UA A201906759A UA A201906759 A UAA201906759 A UA A201906759A UA 122847 C2 UA122847 C2 UA 122847C2
Authority
UA
Ukraine
Prior art keywords
treatment
diabetes
complex
type
diabetic dyslipidemia
Prior art date
Application number
UAA201906759A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кі Сук Парк
Ки Сук Парк
Хє Цзин Йонь
Хе Цзин Йонь
Юн Хук Цзюн
Сунь Вон Кім
Сунь Вон Ким
Цзи Йонь Кім
Цзи Йонь Ким
Сеок Чеол Йо
Рі Сун Кім
Ри Сун Ким
Цзе Сун Ахн
Original Assignee
Елджі Кем, Лтд.
ЭлДжи КЕМ, ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA122847(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елджі Кем, Лтд., ЭлДжи КЕМ, ЛТД. filed Critical Елджі Кем, Лтд.
Publication of UA122847C2 publication Critical patent/UA122847C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UAA201906759A 2016-11-15 2017-11-15 Лікувальний комплекс для лікування діабету другого типу та діабетичної дисліпідемії UA122847C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160152195 2016-11-15
PCT/KR2017/012941 WO2018093144A1 (ko) 2016-11-15 2017-11-15 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제

Publications (1)

Publication Number Publication Date
UA122847C2 true UA122847C2 (uk) 2021-01-06

Family

ID=62146049

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201906759A UA122847C2 (uk) 2016-11-15 2017-11-15 Лікувальний комплекс для лікування діабету другого типу та діабетичної дисліпідемії

Country Status (10)

Country Link
KR (1) KR102055894B1 (es)
CN (1) CN109996545A (es)
BR (1) BR112019009709A2 (es)
CO (1) CO2019005207A2 (es)
MX (1) MX2019005572A (es)
PE (1) PE20191502A1 (es)
PH (1) PH12019501028A1 (es)
RU (1) RU2721406C1 (es)
UA (1) UA122847C2 (es)
WO (1) WO2018093144A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874701A (zh) * 2025-01-14 2025-04-25 深圳格莱恩生物医药科技有限公司 一种吉格列汀马来酸盐晶体及其制备方法与应用
CN120004890B (zh) * 2025-02-17 2025-10-21 安徽峆一药业股份有限公司 一种吉格列汀盐酸盐微晶及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
ES2477868T3 (es) * 2005-04-22 2014-07-18 Alantos Pharmaceuticals Holding, Inc. Inhibidores de dipeptidil peptidasa-IV
EP2464344A2 (en) * 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
KR20120107080A (ko) * 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제
TWI606848B (zh) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
CN103494788B (zh) * 2013-10-10 2015-08-05 齐晓彤 瑞舒伐他汀钙片的药物组合物及其制备方法
CN104473929B (zh) * 2014-12-17 2018-05-29 深圳翰宇药业股份有限公司 一种西格列汀辛伐他汀缓释组合物

Also Published As

Publication number Publication date
KR20180054500A (ko) 2018-05-24
CN109996545A (zh) 2019-07-09
BR112019009709A2 (pt) 2019-08-13
KR102055894B1 (ko) 2019-12-13
PH12019501028A1 (en) 2020-01-20
WO2018093144A1 (ko) 2018-05-24
RU2721406C1 (ru) 2020-05-19
MX2019005572A (es) 2019-08-14
PE20191502A1 (es) 2019-10-22
CO2019005207A2 (es) 2019-08-20

Similar Documents

Publication Publication Date Title
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
MY195561A (en) Indole Carboxamide Compounds useful as Kinase Inhibitors
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA201201657A1 (ru) Лечение диабета
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112018007026A2 (pt) composto, método de modulação da atividade de gaba-at, método para a modulação dos níveis de dopamina, método para o tratamento da dependência de substâncias, método de modulação da atividade de ornitina aminotransferase, método de redução da atividade de uma ornitina aminotransferase expressa por um carcinoma hepatocelular humano e método para o tratamento de distúrbios psicológicos e neurológicos
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MX391627B (es) Aplicación cuantitativa periorbital de fármacos oftalmológicos.
EP3590338A3 (en) Medical treatments based on anamorelin
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
MX2021007477A (es) Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer.
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
PH12019501028A1 (en) Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
FI3448430T3 (fi) Asetyylikoleeniesteraasi-inhibiittorin ja idalopirdiinin käyttö Parkinsonin taudin potilaiden kaatumisten vähentämiseksi
MY187357A (en) Pharmaceutical composition comprising bisoprolol and perindoril